Gilenya® shown to reduce MS relapse rates

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Gilenya® shown to reduce MS relapse rates

Postby MSUK » Thu Oct 03, 2013 1:19 am

Gilenya® shown to reduce MS relapse rates compared to interferons or glatiramer acetate

Novartis announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya® (fingolimod) in reducing risks of relapses compared to standard therapies. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark....... Read More - http://www.ms-uk.org/gilenya
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2119
Joined: Wed Oct 14, 2009 3:00 pm

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service